In a live virtual event, Attaya Suvannasankha, MD, discussed the MajesTEC-1 trial of teclistamab and approaches to mitigation ...

Flavor Flav is owning up to his mistakes - and moving forward. On Thursday, the Public Enemy rapper revealed that he recently ...

The Public Enemy co-founder admitted to fans that he had "briefly relapsed." He said he wants to “hold myself publicly ...

A real-world study has reinforced the efficacy and safety of teclistamab in heavily pretreated patients with ...

Flav, born William Jonathan Drayton Jr., has received widespread praise for his honesty around addiction and recovery. His ...

Iconic rapper and reality television star Flavor Flav has openly discussed a brief relapse in his journey to sobriety, ...

ECHELON-3 (NCT04404283) principal investigator Craig A. Portell, MD, speaks to the significance of this triplet approval from ...

A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

News; Entertainment; Bollywood; Tahira Kashyap, battling breast cancer for the second time, gets spooked by doctor's choice ...

Discover the long-term results of CAR T-cell therapy, with and without stem cell transplantation, for relapsed lymphoma ...

“We’re advancing REC-3565, a potential best-in-class MALT1 inhibitor, to improve outcomes for patients with B-cell malignancies with limited treatment options,” said David Mauro, Chief Medical Officer ...